Abstract: Nuclear medicine offers ideal techniques to visualize inflammatory processes using noninvasive methods of whole-body scanning, enabling the determination of both the localization and the number of inflammatory foci. In nuclear medicine, a radiolabeled compound is injected (mostly) intravenously and accumulates in the inflammatory lesion due to the locally changed physiological condition. These changes are enhanced blood flow, enhanced vascular permeability and enhanced influx of leukocytes. Radiopharmaceuticals can be primarily divided into two classes: those accumulating in the inflammatory lesion based on non-specific processes and those accumulating in connection to leukocytes. Nonspecific tracers like 67 Ga-citrate, radiolabeled non-specific immunoglobulins and radiolabeled liposomes are discussed in detail. Studies using specific tracers mainly focus on radiolabeling leukocytes, either directly or indirectly. Direct labeling of isolated leukocytes and reinjecting them is considered the "gold standard" nuclear medicine technique for imaging inflammation. Labeling leukocytes in vivo (the indirect approach) can be achieved by the use of radiolabeled antibodies or by compounds binding to leukocyte receptors with high affinity. At least three anti-granulocyte antibodies have been tested for infection imaging: anti-NCA-95 IgG (BW250/183), anti-NCA-90 Fab' (Immu-MN3, leukoscan®: anti-CD66), and anti-SSEA-1 IgM (LeuTech ® : anti-CD15). In addition, a w ide var iety of pe ptide s binding to le ukocyte re ceptors ha s be en inve stiga ted, e.g. chemota ctic pe ptide formyl-Me t-L eu-Phe, cytokines such as inte rleukin-1, inte rleukin-2, inte rleukin-8 and pla te let f actor 4 (deriva tives) a nd complement f ac tor s suc h as C5a. Furthermore, positron emission tomography with 18 Ffluorodeoxyglucose takes advantage of the enhanced glucose requirements of leukocytes and macrophages in inflammatory foci. A totally different approach is to target directly micro-organisms, without intervention of leukocytes. This strategy is adopted in radiopharmaceuticals such as Infecton and antimicrobial peptides. The discussed radiopharmaceuticals enable accurate diagnosis of the inflammatory condition and with these agents the effectiveness of anti-inflammatory therapies can be monitored.
INTRODUCTION
Inflammatory diseases, both infectious and noninfectious, are a prominent problem in clinical practice. Detection and localization is a challenging item in clinical practice, because it may have important implications for the treatment of patients with presumed or established inflammatory disorders. Scintigraphic detection of inflammation makes possible the determination of both the localization and the number of inflammatory foci throughout the body. Since scintigraphic images are based on functional (physiological and/or biochemical) changes of tissues, inflammatory processes can be visualized in their early phases, when anatomical changes are not yet apparent. Moreover, the effectiveness of anti-inflammatory therapies can be monitored since scintigraphic imaging enables accurate staging of inflammatory diseases. Over the last 30 years multiple approaches to visualize inflammatory foci using radionuclides and gamma cameras have been developed.
All inflammatory processes develop along a known sequence: locally increased blood supply, leakage of fluid, small molecules and proteins, and infiltration of cells [1] .
*Address correspondence to this author at the Department of Nuclear Medicine, University Medical Center Nijmegen, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands; Tel: +31-24-3615054; Fax: +31-24-3618942; E-mail: H.Rennen@nugen.azn.nl Scintigraphic imaging of inflammation can be achieved in various ways, depending on which aspect of the inflammatory process is to be addressed (Fig. (1) , Table (1)) . Nonspecific markers utilize the locally enhanced blood supply and the locally enhanced vascular permeability and show increased extravasation at the site of inflammation. Examples are 67 Ga-citrate, radiolabeled non-specific immunoglobulins and radiolabeled liposomes. It must be emphasized that all radiopharmaceuticals accumulate to some extent in this non-specific way in inflammatory foci [2] . This is of particular importance when evaluating new radiotracers that pretend to accumulate in inflammatory foci in a specific way. Non-specific accumulation can be erroneously interpreted as specific accumulation.
The second approach is to exploit the diapedesis and chemotaxis of leukocytes, either by radiolabeling white blood cells of the patient ex vivo or by directly targeting leukocyte antigens or receptors in vivo via administration of radiolabeled antigranulocyte monoclonal antibodies (anti-NCA-95 IgG, anti-NCA-90 Fab' and anti-SSEA-1 IgM) or receptor-binding ligands (chemota ctic peptides , cytokines a nd complement fac tors). The accumulation of these agents at the site of inflammation is thought to be at least in part specific, i.e. the radiopharmaceutical specifically binds to the target. Different leukocyte subpopulations can be targeted with different agents. Most of the investigated agents bind preferentially to granulocytes and are most suitable to visualize acute inflammatory processes. Few agents, such as radiolabeled cytokine Interleukin-2, bind preferentially to lymphocytes and are suitable for monitoring chronic inflammatory processes.
Positron emiss ion tomogra phy (PET) scans using 18 Ffluorodeoxyglucose (FDG) have a completely different mechanism of accumulation at the inflammatory site: Enhanced uptake of radiolabeled glucose by infiltrated granulocytes and tissue macrophages with increased metabolic requirements. The accumulation of 18 FDG in cells with increased glucose metabolism is specific. However, 18 FDG is taken up also by tumor cells. So, accumulation of 18 FDG is not specific for inflammatory processes as such.
A new class of radiopharmaceuticals specifically bind to micro-organisms (Infecton and antimicrobial peptides). However, the specific nature of uptake in inflammatory lesions of these radiopharmaceuticals is still a matter of debate.
In this paper the characteristics of the radiopharmaceuticals that are currently used to visualize inflammatory processes are reviewed. In addition, the status and potential of the agents that are currently under development are discussed. An overview of the scope, advantages and limitations of the agents is presented in Table ( 2). 67 Ga-citrate 67 Ga-citrate is used in clinical practice in several pathological conditions, including inflammatory and skeletal disorders [3, 4] . 67 Ga-citrate binds, once injected in the circulation, to circulating transferrin. This complex extravasates at the site of infection due to the locally enhanced vascular permeability [5] , and is partly bound there to lactoferrin excreted by leukocytes or to siderophores Fig. (1) . Schematic representation of the inflammatory response. The noxious stimulus of the anti-inflammatory response can be either biotic (infection) or non-biotic (inflammation). In response inflammatory mediators are generated by the locally present macrophages and mast cells, in order to increase tissue perfusion and vascular permeability (vasoactive mediators), and to attract leukocytes to the site of inflammation (chemoattractants). Leukocytes marginate by upregulation of adhesion molecules on both endothelial cells and the leukocytes themselves. They pass through the gap between the endothelial cells and migrate up the chemotactic gradient to the site of inflammation, where they remove the noxious stimulus by phagocytosis. produced by microorganisms [6] . The age nt is e xcreted pa rtly via the kidneys (es pec ia lly during the first 24 hours after inje ction), and via the gas trointe stina l tra ct. Phys iologic al upta ke of the ra diola be l occ urs in liver, bone , bone marrow a nd bowe l. Although 67 Ga -c itrate sc intigra phy has high se nsitivity for both acute and chronic infec tion and noninfec tious inflammation [7] , there are s eve ra l s hortc omings tha t limit its clinica l application. The s pe cific ity of the te chnique is low, due to phys iologic al bowel e xcretion a nd ac cumulation in ma ligna nt tiss ues a nd areas of bone modeling [8] [9] [10] . In addition, the ra diopharmac eutic al ha s unfavora ble ima ging characteristic s (long physica l half-life a nd high energy ga mma photons ), ca us ing high radiation a bsorbed doses . Furthermore, optimal imaging often re quire s delaye d rec ordings up to 72 hours. These unfa vorable characteristic s, in combina tion with the development of new er ra diopharmac eutic als, ha ve na rrowe d the c linic al indic ation for ga llium sc intigra phy to ce rtain c onditions suc h as lung infec tions a nd chronic os te omyelitis [7, 10] .
NONSPECIFIC UPTAKE IN INFLAMMATORY FOCI

Non-specific immunoglobulins
Initially it was hypothesized that human polyclonal immunoglobulin (HIG) was retained in inflammatory foci due to the interaction with Fc-γ receptors as expressed on infiltrating leukocytes [11] . Later studies have shown that Tc-labeled HIG has been extensively tested in a large number of clinical studies. It has shown excellent performance in the localization of musculoskeletal infection and inflammation [13] . In addition, good results have been reported in pulmonary infection -particularly in immunocompromised patients - [14, 15] , and abdominal inflammation [16] . In a comparative study, Dams et al. showed that 99m Tc-HIG labeled with the Tc-99m chelator hydrazinonicotinamid (HYNIC), has in vivo characteristics highly similar to those of 111 In-HIG, and in most cases can replace the 111 In-labeled compound [17] . Poor sensitivity of radiolabeled HIG is found in the diagnosis of endocarditis and vascular lesions in general, due to long lasting high levels of circulating activity. A general limitation is the long time span between injection and final diagnosis (24-48 h).
Liposomes
Liposomes are microscopically spheres consisting of one ore more lipid bilayers surrounding an aqueous space. They were proposed as vehicles to image inflammatory conditions some 25 years ago, but the preparations used in those early years were cleared from the circulation very rapidly by the mononuclear/phagocyte system (MPS). However, if the surface of the liposomes is coated with a hydrophylic polymer such as polyethyleneglycol (PEG), they circumvent recognition by the MPS. This leads to a prolonged residence time in the circulation and enhanced uptake in pathological sites by extravasation due to locally enhanced vascular permeability [18] . Such stabilized PEG-liposomes can be labeled with 111 In-oxinate and with 99m Tc using either HMPAO as an internal label or via HYNIC as an external chelator. Labeling is easy and takes only minutes [19] . The first clinical evaluation showed good imaging of focal infection [20] . In patients suspected of inflammatory disease, Tc-PEG-liposomes were directly compared to 111 In-IgGscintigraphy. Tc-PEG-liposomes scintigraphy showed high sensitivity (94%) and specificity (89%). Visualization of muscuskeletal and abdominal pathology was better than with 111 In-IgG. Unfortunately, in another clinical study sideeffects were observed, being unacceptable for a diagnostic tool [21] .
The use of non-specific radiotracers to image inflammation
Inflammatory foci can be visualized with radiotracers without a specific interaction between the agent and a tissue component in the inflammatory focus, in a non-specific process of localization due to the locally enhanced vascular permeability. In case one wants to address nonspecific uptake in inflammatory foci exclusively, any of the nonspecific markers mentioned above is suitable. 99m Tc-labeled nonspecific immunoglobulins is the preferred agent with a general availability, low cost and no toxicity of the protein together with an easy labeling technique. However, commercial kits are not available, impeding its general use in the clinic.
ENHANCED INFLUX OF GRANULOCYTES IN INFLAMMATORY FOCI
Ex vivo labeled granulocytes
Radiolabeled autologous granulocytes have been developed in the seventies and eighties [22] [23] [24] and are still considered the "gold standard" nuclear medicine technique for imaging inflammatory processes. Whole venous blood is taken from a patient, the granulocytes are isolated and radiolabeled. After intravenous administration, there is initial sequestration of the labeled granulocytes in the lungs with subsequent rapid clearance of the activity from the lungs. The radiolabel rapidly clears from the blood and in most cases there is high uptake in granulocytic infiltrates, while a substantial portion of the granulocytes (presumably the old and damaged cells) accumulate in the spleen. Thus, as a radiopharmaceutical, radiolabeled granulocytes are a specific indicator for granulocytic infiltration, but not for infection.
McAfee et al. [22] developed a technique to label autologous granulocytes with 111 In using oxinate as a chelate to transfer the radiolabel into the cell. Peters et al. [23] Tc-HMPAO is released from the granulocytes after injection and subsequently excreted renally (within minutes) and hepatobiliary (after hours) [24] . Due to the more optimal radiation characteristics, Tc-labeled granulocytes have replaced 111 In-labeled granulocytes for most indications. Still, for evaluation of kidney, bladder and gall bladder infections the use of granulocytes labeled with 111 In is preferred. The excellent performance of radiolabeled granulocytes for imaging inflammatory processes was demonstrated in a series of studies: for imaging inflammatory foci sensitivity exceeded 95% [24] [25] [26] [27] . There was some concern that more chronic processes could be missed with labeled granulocyte scans, because such processes generate a smaller granulocyte response than acute inflammatory processes. However, a study in 155 patients showed that the sensitivity of labeled granulocytes for chronic processes (86%) was not significantly different from the sensivity for detection of acute processes (90%) [28] . Labeled granulocytes proved to be useful also in the assessment of the extent and severity of acute exacerbations of ulcerative colitis [29] . Because the presence and severity of disease correlated well with endoscopic and histologic findings in this study, it was concluded that granulocyte scintigraphy could assess disease extent without need for colonoscopy. With regard to diagnostic accuracy there is no urgent need for a better imaging agent than labeled autologous granulocytes. However, the preparation of this radiopharmaceutical is laborious, requires specialized equipment and could be hazardous. Isolating and labeling a patient's white blood cells takes a trained technician approximately 3 hours. In addition, the need to handle potentially contaminated blood could lead to transmission of blood-born pathogens such as human immunodeficiency virus (HIV) and hepatitis B virus (HBV) [30] .
In vivo labeled granulocytes
A gross division can be made in radiotracers that bind granulocytes by receptor-binding (relatively small molecules; MW < 20 kDa) and radiotracers that bind granulocytes by antibody-antigen interaction (relatively large molecules). The antibodies range in molecular weight from 50 kDa (antibody fragments) via 150 kDa (IgG) to 900 kDa (IgM).
Radiolabeled antigranulocyte antibodies and antibody fragments
Ever since it became clear that radiolabeled autologous granulocytes could visualize inflammatory foci, investigators have tried to develop a methodology to label granulocytes in circulation or in inflammatory foci. Instead of isolating the white blood cells from a patient and labeling the cells ex vivo, these methods aimed to label white blood cells in vivo. Such labeling procedures can be easier and do not require handling of potentially contaminated blood. The use of radiolabeled monoclonal antibodies against surface antigens as present on granulocytes was one of the first attempts to accomplish in vivo labeling of granulocytes. Several monoclonal antibodies reactive to antigens expressed on granulocytes (NCA, CD15, CD66 and CD67) have been developed. At least three [38] [39] [40] [41] , and anti-SSEA-1 IgM (LeuTech ® : anti-CD15) [42] [43] [44] [45] [46] . Each of these anti-granulocyte antibodies made possible an accurate delineation of inflammatory foci.
It was soon realized that the in vivo behavior of these labeled anti-granulocyte antibody preparations, did not mimick the behavior of radiolabeled granulocytes. In general, blood clearance of the IgG preparations was much slower, giving a high background radioactivity that decreases slowly with time. For that reason the time interval between injection of the labeled antibodies and the acquisition of images is relatively long in order to get good targetbackground ratios. Furthermore, no initial lung entrapment was seen and splenic uptake was much lower, while the preparations based on antibody fragments (Fab, Fab') had a much higher renal excretion. Similarly, the IgM antibody had a much higher liver uptake as compared to the ex vivo labeled white blood cells. Becker et al. showed that less than 10% of the radiolabeled BW250/183 antibody as present in the blood was actually associated with granulocytes [31] . These observations indicated that the anti-granulocyte antibody approach for imaging inflammation, although feasible did not represent a method to label white blood cells in vivo. It is now generally accepted that radiolabeled antigranulocyte antibodies localize in inflammatory foci mainly by nonspecific extravasation as a result of locally enhanced vascular permeability, and that binding of the antibody to infiltrated granulocytes in the inflamed tissue may contribute to the retention of the radiolabel in the focus [31, 37] . Perhaps an exception should be made for anti-SSEA-1 IgM (LeuTech ® : anti-CD15) [42, 46] . This antibody recognizes CD-15 antigens on granulocytes with high affinity (K d = 10 -11 M) and the in vivo granulocyte binding exceeds 50%, pointing towards more specific processes of accumulation in infected tissue. Recently, a 99m Tc-labeled anti-CD15 IgM monoclonal antibody has shown promising results in patients with equivocal appendicitis [43] .
The anti-granulocyte antibody-based radiopharmaceuticals visualized infectious foci in patients with a sensitivity between 80 and 90% [47] . Tc-BW250/183 scintigraphy was useful in the evaluation of vascular graft infection and prosthetic heart valve infection. Good results were also obtained in the evaluation of patients with inflammatory bowel disease [32, 47] , although the agent appeared to be less accurate compared to labeled granulocytes [34, 35] . Pulmonary infections -with the exception of lung abscesseswere not visualized. Peripheral bone infections were adequately visualized, but the sensitivity decreased in case the focus was located closer to the spine [39] . Due to the relatively slow blood clearance of the agent, a 24-hour postinjection scan is generally necessary for correct localization of the inflammatory focus. A major disadvantage of the murine monoclonal antibodies is that they may induce human antimouse antibodies (HAMA), which can result in altered biodistribution after subsequent injections [47, 48] . In this respect, the use of antibody fragments instead of the whole antibody seems to be more advantageous, since such fragments appeared to be less immunogenic [47] . In addition, antibody fragments show faster blood clearance and may thus provide earlier diagnosis. The 99m Tc-labeled antigranulocyte Fab'-fragment (Leukoscan®) has been registered in Europe as an infection imaging agent [38] . Further clinical studies will help to define the utility of these new agents in clinical practice.
Radiolabeled receptor-binding peptides and proteins
The enhanced influx of white blood cells in inflammatory foci could be addressed in an alternative approach, based on interactions with receptors on these cells. The binding of labeled agents to receptors on white blood cells, either in circulation or in inflammatory foci, theoretically may allow specific uptake in these tissues. It appears that small receptor-binding peptides could fulfil most of the requirements for an ideal radiotracer for imaging inflammation and infection as summarized in Table (3) . Their smaller size facilitates rapid clearance from the background resulting in high target-to-background ratios in a relatively short time. Recently, much attention has been directed towards labeling of mediators of the inflammatory response (chemotactic peptides, cytokines a.o.) for the purpose of imaging inflammatory processes.
Chemotactic peptides
One of the first peptides binding to receptors on white blood cells that was studied for its ability to image inflammatory foci was the chemotactic peptide formyl-MetLeu-Phe. This tripeptide that is N-terminally formylated, is a chemotactic factor produced by bacteria. It binds to receptors on granulocytes and monocytes with high affinity (K d = 10-30 nM). The first work on this radiolabeled chemotactic peptide was reported twenty years ago. Zoghbi et al. labeled f-Met-Leu-Phe and investigated its in vivo characteristics [49] . They found that even low doses of peptide induced a transient granulocytopenia. In 1991, Fischman et al. described the synthesis of four chemotactic peptide analogs and their labeling with 111 In [50] . For all peptides biologic activity and receptor binding affinity was preserved. The peptides were tested in rats with Escherichia coli soft tissue infections. All analogs showed preferential localization in the focal infection within one hour after injection. In a comparative study in rabbits with E. coli infections, it was demonstrated that localization of infection using 99m Tclabeled f-Met-Leu-Phe was superior to that of 111 In-labeled granulocytes [51] . However, although a high specific activity 99m Tc-labeling method was applied, a peptide dose as low as 10 ng/kg still resulted in a drop of the peripheral granulocyte counts [52] . Several antagonists were developed to circumvent this undesirable biologic activity of the radiolabeled chemotactic peptide. However, these antagonists had lower uptake in the infectious focus, most likely due to reduced affinity for the receptor [53, 54] . In summary, rapid imaging of inflammatory conditions is feasible with radiolabeled chemotactic peptides. However, the undesired biologic side-effects of these peptides seem to impede further clinical development.
Cytokines
Labeled cytokines are a potential class of protein radiopharmaceuticals of small molecular weight (< 20 kDa). Cytokines act through an interaction with specific cellsurface receptors expressed on known cell populations. Binding affinities are usually high (nanomolar range). The majority of the cytokines under investigation are proteins binding to receptors predominantly present on granulocytes. These are potentially the best markers for acute inflammatory processes. A well studied cytokine binding predominantly to receptors on lymphocytes is Interleukin-2, thus being a marker for chronic inflammatory processes.
Interleukin-1 (IL-1)
IL-1 binds receptors as expressed mainly on granulocytes, monocytes and lymphocytes, with high affinity. Studies in mice with focal Staphylococcus aureus infections showed specific uptake of radioiodinated IL-1 at the site of infection [55] . Using IL-1 receptor blocking antibodies, it could be demonstrated that accumulation of the agent in the infectious foci was due to binding to the IL-1 type II receptor [56] . Unfortunately, the biologic effects (e.g., hypotension, headache) of IL-1 even at very low doses (10 ng/kg) precluded clinical application of radiolabeled IL-1. Therefore, the naturally occurring IL-1 receptor antagonist (IL-1ra) was tested as an imaging agent. This equally-sized (17 kDa) protein binds IL-1 receptors with similar high affinity but lacks any biologic activity. In a comparative study in rabbits with focal E. coli infections, the abscess uptake of radioiodinated IL-1ra was half that of radioiodinated IL-1 [57] .
123 I-IL-1ra was tested in patients with rheumatoid arthritis. In these patients, inflamed joints were nicely visualized, however, major retention of the radiolabel in the intestinal tract indicated that this agent can not be used to visualize inflammatory lesions in the abdomen [58] .
Interleukin-8 (IL-8)
IL-8 is a small protein (8.5 kDa) belonging to the CXC subfamily of the chemokines, or chemotactic cytokines, in which the first two cysteine residues are separated by one aminoacid residue. IL-8 binds to receptors on neutrophils with high affinity (0.3 -4 nM). Hay and colleagues [59] studied the in vivo behaviour of radioiodinated IL-8 in a rat model with carrageenan-induced sterile inflammations. The uptake peaked at 1-3 hours after injection and declined thereafter. Target-to-background ratios remained relatively low. In a pilot study in 11 patients Gross and colleagues showed that 123 I-IL-8 could visualize inflammatory foci [60] . The labeling method appeared to have major effects on the in vivo biodistribution of radioiodinated IL-8. The scintigraphic imaging characteristics of IL-8 labeled via the Bolton-Hunter method were clearly superior to IL-8 labeled via the iodogen method, despite similar in vitro cell binding characteristics [61] . In rabbits with focal E. coli infection, accumulation of 123 I-labeled IL-8 in the abscess was rapid and high. The specific activity of this IL-8 preparation was relatively low resulting in a transient drop of peripheral granulocyte counts to 45% after a dose of 25 µg/kg 123 I-IL-8, followed by a granulocytosis (170 % of preinjection level) during several hours. Recently, a 99m Tc-labeled IL-8 preparation was developed using HYNIC as a chelator. In rabbits with thigh muscle infection induced by E. coli, high abscess uptake of 99m Tc-HYNIC-IL-8 and high abscess-background ratios were obtained compared to those using the radioiodinated preparation [62] . In rabbits with chemically induced acute Tc-HYNIC-IL-8 [63] . Within 4 h after injection, this agent allowed a meticulous evaluation of the severity of inflammatory bowel disease. The performance of 99m Tc-HYNIC-IL-8 was also evaluated in a rabbit model of acute osteomyelitis [64] . In this model, Tc using HYNIC as a chelator could be further optimized by the use of alternative coligands to stabilize the 99m Tc-protein-complex [65] . The most optimal infection imaging characteristics in a rabbit model of E. coli induced thigh muscle infection were found for formulations using nicotinic acid and tricine as coligands. This formulation combined a high specific activity and high in vitro stability with high abscess/muscle ratios and high abscess/background ratios. In this way, protein doses to be administered could be lowered substantially for this highly bioactive protein.
Platelet Factor 4 (PF-4)
PF4 is like IL-8 a member of the CXC chemokines. PF4 has been called the "body's heparin neutralizing agent". The imaging characteristics of 99m Tc-labeled PF4 were compared to those of IL-8 in a rabbit model of soft tissue infection [66] . Abscess uptake of PF4 was considerably lower and liver uptake considerably higher. Thus, Tc-labeled native PF4 is an unfavorable alternative for infection imaging. At Diatide Inc. the peptide P483H was synthesized. This peptide contains the heparin-binding region of PF4 -complexed with heparin -and a lysine-rich sequence to facilitate rapid renal clearance and to reduce liver uptake. In a rabbit model of infection, Tc-P483H has been studied in patients to test its applicability as imaging agent for scintigraphic detection of infection and inflammation with fair results (sensitivity 82-86%, specificity 77-81%) [68, 69] . However, in some patients excessive thyroid uptake was observed, suggesting the release of 99m Tc from the agent in vivo.
Other cytokines
Other neutrophil binding mediators like NAP-2, ENA-78, GCP-2, IP-10 and the GRO-proteins (GRO-α, -β, -γ) theoretically could also be used as infection imaging agent. In a preclinical study the imaging c ha rac te ris tics of a 99m Tcla be led G CP-2 derivative we re compare d to those of IL-8 [66] . He re again, IL-8 prove d to be the superior a gent: absc ess upta ke and a bs ces s to muscle ratios w ere 4 time s as high as for the GCP-2 de rivative.
Complement factors
The complement anaphylatoxin C5a and its natural metabolite C5a -des-Arg are involved in several stages of the inflammatory process. C5a-des-Arg differs from C5a in only one aminoacid residue: it lacks the C-terminal Arg-residue of C5a. Both act on a common receptor on different cell types, including neutrophils and monocytes. The receptor binding affinity of C5a exceeds that of C5a -des-Arg by 1-2 orders of magnitude. The biologic potency of C5a-des-Arg is considerably reduced as compared to that of C5a. A study with 99m Tc-labeled C5a and C5a-des-Arg in rabbits with E. coli induced thigh muscle infections showed that 99m Tclabeled C5a could rapidly visualize the inflammatory focus with considerably high uptake of the radiolabel in the affected muscle [70] . The antagonist C5a-des-Arg showed low uptake in infection. The ideal combination of reduced biological potency and preferable imaging characteristics was not found in C5a-des-Arg.
ENHANCED INFLUX OF LYMPHOCYTES IN INFLAMMATORY FOCI
Interleukin-2 (IL-2)
Chronic inflammation is characterized by lymphocyte infiltration into the target tissue. These infiltrating cells have been successfully targeted with radiolabeled IL-2. IL-2 is considered to bind specifically to IL-2 receptors as expressed on activated T-lymphocytes. In a study in an animal model of human autoimmune diabetes mellitus, Signore et al. showed that lymphocytic infiltration in the pancreas could be visualized with 123 I-labeled IL-2 between five and fifteen minutes after injection [71] . A method was developed that allowed the preparation of a 99m Tc-IL-2 radiopharmaceutical with a high specific activity [72] . Studies in patients with chronic inflammatory conditions, including insulindependent diabetes, Hashimoto thyroiditis, Graves' disease, Crohn's disease, coeliac disease and other autoimmune diseases, demonstrated localization of 123 I-or 99m
Tc-labeled IL-2 at the site of lymphocytic infiltration [73] [74] [75] . In cases of Crohn's disease, the intestinal 123 I-IL-2 uptake positively correlated with the Crohn's disease activity index [74] . A study in patients with coeliac disease demonstrated a positive correlation between the number of lymphocytes infiltrating the jejunal mucosa, histologically determined, and the jejunal accumulation of 123 I-IL-2 measured by gamma-camera [75] . The results suggested that radiolabeled IL-2 might be a suitable agent for in vivo targeting of mononuclear cell infiltration as present in autoimmune diseases.
ENHANCED GLUCOSE UPTAKE BY ACTIVATED WHITE BLOOD CELLS
Positron emission tomography (PET) using 18 
FDG
The use of 18 F fluorodeoxyglucose positron emission tomography (FDG-PET) has become increasingly important for differentiating malignant from benign tumors, for tumor staging, and for evaluating treatment efficacy in cancer patients [76, 77] . As early as 1931, Warburg has demonstrated an increased glucose metabolism in malignant tumors in vitro [78] . FDG accumulates in malignant tumors in vivo mainly due to their increased glucose metabolism. However, during staging and follow-up of malignant tumors, false-positive findings occasionally occurred, mainly due to inflammatory or granulomatous processes [79] . Ever since Tahara et al. first demonstrated high FDG uptake in human abdominal abscesses in 1989 [79] , FDG has been reported to accumulate in various inflammatory processes. Imaging inflammation with FDG-PET is based on the fact that granulocytes and macrophages use glucose as an energy source. When activated, metabolism and thus FDG-uptake increases. The usefulness of FDG-PET to image infections has recently been demonstrated in several patient studies [80] [81] [82] [83] [84] [85] [86] [87] . FDG-PET has been studied in a wide variety of infections, including lesions of baterial, tuberculous and fungal origins, soft tissue infections as well as bone infections. Sensitivities and specificities generally exceeded 90%. FDG-PET has been especially successful in cases of osteomyelitis [82, 83, [85] [86] [87] . The high spatial resolution allows differentiation between osteomyelitis or inflammatory spondylitis and infection of the soft tissue surrounding the bone [86] . High spatial resolution and rapid accumulation into infectious foci are significant advantages over conventional imaging techniques such as labeled granulocytes. However, the high degree of unspecificity due to uptake in any cell type with high glycolytic activity is a serious limitation of the use of FDG-PET for imaging inflammatory disorders. E.g., FDG-PET does not allow the discrimination between tumor lesions and inflammatory lesions. Depending on the clinical setting, this may restrict the usefulness of FDG-PET in the imaging of inflammation. Moreover, FDG uptake in inflammatory foci is affected by serum glucose levels and by conditions as diabetes mellitus. Cost is another issue. FDG-PET is a rather expensive imaging modality and prospective studies in various patient populations will have to show the cost-effectiveness of FDG-PET for imaging of inflammatory diseases.
TARGETING MICROORGANISMS
Ciprofloxacin (Infecton)
None of the agents discussed above can make a differential diagnosis between infection and sterile inflammation as they accumulate in the focus due to a common feature of infection and sterile inflammation. Ciprofloxacin, a fluoroquinolone antimicrobial agent, binds to the DNA gyrase enzyme present in all dividing bacteria, even to those resistant to ciprofloxacin. Fluoroquinolones are thought not to bind to dead bacteria nor to accumulate in non-microbial inflammatory processes such as Crohn's disease. Originally, it was claimed that with these 99m Tclabeled agents it is possible to discriminate between infection and sterile inflammation [88] . First clinical studies showed high accuracy in the detection of bacterial infection. Data on the efficacy of imaging using a 99m Tc-ciprofloxacin derivative called "Infecton" in patients with suspected infective disorders revealed sensitivities between 70 and 94% and specificities between 83 and 93% [89] [90] [91] . Repeat studies on patients following antibiotic treatment over a long period seemed to be very useful in deciding on termination of this treatment [91] . However, results with Infecton gathered by another group pointed towards good sensitivity but lack of specificity in a study in rabbits with infected/non infected knee prosthesis [92] and in patients after joint arthroplasty or surgical osteosynthesis (specificity only 31%) [93] .
Antimicrobial peptides
Neutrophil defensins (human neutrophil peptides, HNP) are stored in the granules of neutrophils. In addition to their direct antimicrobial activity, the peptides have chemoattractive activity for various monocytes and lymphocytes. It has been hypothesized that their cationic charge facilitates binding of these peptides to various micro-organisms. HNP-1 was labeled with 99m Tc using a direct method by reducing the disulfide bridges of the molecule. Using this agent in experimental thigh infections in mice abscess-to-background ratios were low and decreasing with time [94, 95] . In the peritoneal cavity of infected mice, Tc-HNP-1 bound to bacteria rather than to granulocytes. However, this agent needs extensive optimization and tailoring to become able to distinguish between bacterial infection and sterile inflammation.
CONCLUSION
Nuclear medicine offers techniques to address individual aspects of inflammatory processes, as summarized in Table  (1) . To address nonspecific uptake in inflammatory foci exclusively, any of the non-specific markers mentioned is suitable, with a preference for 99m Tc-labeled nonspecific immunoglobulins. Enhanced influx of granulocytes in inflammatory foci can be visualized basically in two ways. Direct labeling of isolated granulocytes and reinjecting them is considered the "gold standard" nuclear medicine technique for imaging inflammation, but this is a cumbersome method, not free of hazards. Labeling granulocytes in vivo (the indirect approach) is getting more and more attention in nuclear medicine. Radiolabeled antigranulocyte antibodies do have attractive features, but lack specificity of uptake in inflammatory foci with a possible exception for the radiolabeled anti-CD15 IgM monoclonal antibodies. The most interesting group of inflammation targeting agents are the chemotactic mediators. This group presents several small hydrophylic proteins and peptides that bind with high affinity to receptors abundantly present in the area of inflammation. Some of these mediators combine high uptake in infectious and inflammatory foci with rapid background clearance. Several chemotactic peptides and cytokines (IL-1, IL-2, IL-8, PF-4 a.o.) are currently under investigation. Using granulocyte binding peptides (IL-1, IL-8, PF-4), acute inflammatory processes could be monitored. IL-2 binds to lymphocytes and appeared to be useful in monitoring chronic inflammatory processes. Potential biologic effects is still the major drawback in the use of these molecules for scintigraphic imaging. This problem has to be addressed on a radiochemical rather than a biochemical level. Attempts to introduce radiolabeled receptor antagonists for imaging of inflammation to replace their biologically potent counterparts have failed so far. Development of high specific activity labeling of agonists appears to be a more fruitful approach. There is an ongoing progress in the selection and optimization of these agents, although to date the development of these agents is still in a relatively early phase. In future studies an extensive clinical evaluation is necessary in order to elucidate whether these receptorspecific small proteins and peptides are suitable as new radiopharmaceuticals for scintigraphic detection of infection and inflammation. In addition, 18 FDG-PET may prove to be as useful in the rapid detection and management of human infections, as it is for management of malignant diseases. Directly targeting micro-organisms present in inflammatory foci using radiolabeled antibiotics is still in a premature state, since the radiopharmaceuticals currently under investigation showed a lack of specificity. 
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